Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients - Czech Center experience

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	WEINBERGEROVÁ Barbora ČERŇAN Martin KABUT Tomáš SEMERÁD Lukáš PODSTAVKOVÁ Natália SZOTKOWSKI Tomáš JEŽÍŠKOVÁ Ivana MAYER Jiří
Year of publication	2023
Type	Article in Periodical
Magazine / Source	Haematologica
MU Faculty or unit	Faculty of Medicine
Citation
Web	https://haematologica.org/article/view/haematol.2022.282263
Doi	http://dx.doi.org/10.3324/haematol.2022.282263
Keywords	Gemtuzumab ozogamicin; midostaurin; acute myeloid leukemia
Attached files	Gemtuzumab_ozogamicin_plus_midostaurin_in_conjunction_with_standard_intensive_therapy_for_FLT3-_mutated_acute_myeloid_leukemia_patients_-_Czech_Center_experience.pdf
Description	For more than four decades, conventional therapy for acute myeloid leukemia (AML) has been represented by cytarabine/anthracycline-containing regimens, followed by consolidation therapy, including allogeneic hematopoietic stem cell transplantation (allo-HSCT). In recent years, approach to the treatment of AML has significantly shifted toward the use of novel and effective, target-directed therapies, including anti-CD33 immunoconjugate, gemtuzumab ozogamicin (GO), and inhibitor of mutant FMS-like tyrosine kinase 3 (FLT3), midostaurin (MIDO).
Related projects:	National institute for cancer research